AB vs FULT

The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score, raising concerns about bankruptcy risk assessment. Despite a high dividend yield of 8.73%, the payout ratio of 111.92% is unsustainable, supported by negative profit margin and declining revenue. Valuation appears stretched relative to intrinsic metrics, with the stock trading at $38.96 versus a Graham Number of $29.35 and intrinsic value of $20.72. Negative insider sentiment, deteriorating growth trends, and weak technicals further reinforce a bearish outlook.

FULT presents a stark contrast between deep value and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the stock trades at a significant discount to both its Graham Number ($29.29) and Intrinsic Value ($61.36), the bearish technical trend and insider selling suggest caution. Strong earnings growth (46.5% YoY) and a consistent track record of beating estimates provide a bullish counter-narrative, but the low health score indicates underlying operational or financial instability. Overall, it is a high-value play with concerning health metrics.